Polycystic Ovary Syndrome (PCOS) Renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS)

Polycystic Ovary Syndrome (PCOS) has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a global consensus process. This change, set out in a paper published in The Lancet in June, aims to better reflect the condition's complex metabolic identity beyond ovarian cysts, which are not always a reliable marker. The new name emphasizes its links to insulin resistance and long-term cardiovascular risks, and highlights the broader health impacts and lifelong issues associated with the condition.